Primary Open Angle Glaucoma Pipeline Analysis Report 2026

Report Coverage

The Primary Open Angle Glaucoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into primary open angle glaucoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for primary open angle glaucoma. The primary open angle glaucoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The primary open angle glaucoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with primary open angle glaucoma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to primary open angle glaucoma.

Read more about this report - Request a Free Sample

Primary Open Angle Glaucoma Pipeline Outlook

Primary open-angle glaucoma is a chronic eye disease characterized by progressive damage to the optic nerve, often associated with elevated intraocular pressure (IOP). It occurs when the eye’s drainage system becomes less efficient, causing fluid to accumulate and pressure to increase. Without timely diagnosis and treatment, optic nerve damage can lead to irreversible vision loss.

Primary open-angle glaucoma treatment focuses on lowering intraocular pressure using prescription eye drops, including prostaglandin analogs, beta blockers, and other medications. Laser therapy and surgery may be considered when medications do not adequately control pressure or prevent disease progression. In February 2024, the US Food and Drug Administration approved generic latanoprost 0.005% from Gland Pharma Limited for open-angle glaucoma and ocular hypertension. This prostaglandin analog eye drop reduces elevated intraocular pressure and represents a treatment option in the glaucoma drug market.

Primary Open Angle Glaucoma Epidemiology

According to Jonathan S. Myers et al. (2025), glaucoma accounts for 9%–12% of blindness cases in the United States. As per Mingxue Bao et al. (2025), the prevalence of primary open-angle glaucoma (POAG) in Japan is 3.9% among individuals aged 40 years and older, compared with 0.6% for primary angle-closure glaucoma. The substantial prevalence of POAG highlights the need for early diagnosis and effective intraocular pressure management. These epidemiological trends support continued primary open-angle glaucoma drug pipeline development to address unmet treatment needs and reduce the risk of irreversible vision loss.

Primary Open Angle Glaucoma – Pipeline Therapeutic Assessment

Primary Open Angle Glaucoma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to Expert Market Research analysis, phase II III, and IV at 28% covers a major share of the total primary open angle glaucoma clinical trials. Phase I is at 16%. The strong representation across mid- and late-stage development supports continued treatment innovation, potential improvements in disease management, and expanded therapeutic options, contributing to the future growth.

Primary Open Angle Glaucoma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the primary open angle glaucoma pipeline analysis include small molecules, oligonucleotides, and peptides. The primary open angle glaucoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for primary open angle glaucoma. Drug therapies targeting alternative mechanisms of intraocular pressure reduction are emerging in the primary open-angle glaucoma drug pipeline. For instance, QLS-111, a topical ATP-sensitive potassium channel modulator developed by Qlaris Bio, demonstrated positive results in two Phase II clinical trials in 2025. It reduces intraocular pressure by lowering distal outflow resistance and episcleral venous pressure, offering a potential treatment option for patients with primary open-angle glaucoma.

Primary Open Angle Glaucoma Clinical Trials – Key Players

The EMR report for the primary open angle glaucoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed primary open angle glaucoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in primary open angle glaucoma clinical trials:

• iVIEW Therapeutics Inc.
• AbbVie
• Kukje Pharma
• Huons Co., Ltd.
• Regeneron Pharmaceuticals
• Qingdao WanMing BioCell Pharmaceutics Co., Ltd.
• Ache Laboratorios Farmaceuticos S.A.
• PolyActiva Pty Ltd.
• YS Life Science Co., Ltd.
• 4B Technologies Limited

Primary Open Angle Glaucoma – Emerging Drugs Profile

Key Questions Answered in the Primary Open Angle Glaucoma Pipeline Insight Report

• Which companies/institutions are leading the primary open angle glaucoma drug development?
• Which company is leading the primary open angle glaucoma pipeline development activities?
• What is the current primary open angle glaucoma commercial assessment?
• What are the opportunities and challenges present in the primary open angle glaucoma pipeline landscape?
• What is the efficacy and safety profile of primary open angle glaucoma pipeline drugs?
• Which company is conducting major trials for primary open angle glaucoma drugs?
• Which companies/institutions are involved in primary open angle glaucoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in primary open angle glaucoma?

Reasons To Buy This Report

The primary open angle glaucoma pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for primary open angle glaucoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into primary open angle glaucoma collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Primary Open Angle Glaucoma Epidemiology Forecast

Glaucoma Pipeline Analysis